Wednesday, 26 January 2022

ANDA approval received by Glenmark Pharmaceuticals for Desonide Cream, 0.05%

31 July 2017 | News

Glenmark’s current portfolio consists of 120 products authorized for distribution in the U.S. marketplace and 65 ANDA’s pending approval with the U.S. FDA

Source: Pixabay

Source: Pixabay

Glenmark Pahrmaceuticals Inc., USA has received an approval by the United States Food & Drug Administration (USFDA) for Desonide Cream, 0.05%.

It is the generic version of Desonide Cream, 0.05% of Perrigo New York Inc.

According to IMS Health sales data for the 12 month period ending May 2017, the Desonide Cream, 0.05% market1 achieved annual sales of approximately $44.6 million.

Glenmark’s current portfolio consists of 120 products authorized for distribution in the U.S. marketplace and 65 ANDA’s pending approval with the U.S. FDA.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account